High expression of SYND4 (the gene encoding SDC4) was associated with reduced RFS (HR = 1.38, p = 0.04) in TNBC patients (Figure 5K), highlighting its potential role in promoting tumor progression through matrix-mediated mechanisms. Here, SDC4 is linked to neoplasm.